Kiran Virik

846 total citations
25 papers, 493 citations indexed

About

Kiran Virik is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Pediatrics, Perinatology and Child Health. According to data from OpenAlex, Kiran Virik has authored 25 papers receiving a total of 493 indexed citations (citations by other indexed papers that have themselves been cited), including 15 papers in Oncology, 10 papers in Pulmonary and Respiratory Medicine and 5 papers in Pediatrics, Perinatology and Child Health. Recurrent topics in Kiran Virik's work include Gastric Cancer Management and Outcomes (7 papers), Colorectal Cancer Treatments and Studies (6 papers) and Palliative Care and End-of-Life Issues (5 papers). Kiran Virik is often cited by papers focused on Gastric Cancer Management and Outcomes (7 papers), Colorectal Cancer Treatments and Studies (6 papers) and Palliative Care and End-of-Life Issues (5 papers). Kiran Virik collaborates with scholars based in Canada, Australia and United Kingdom. Kiran Virik's co-authors include Paul Glare, Daniel Rayson, Turki Alfayea, Tallal Younis, Nathalie Saint‐Jacques, Steven J. Cohen, Christian Kollmannsberger, Georg A. Bjarnason, Patricia A. Tang and Malcolm J. Moore and has published in prestigious journals such as Journal of Clinical Oncology, Clinical Cancer Research and Annals of Oncology.

In The Last Decade

Kiran Virik

25 papers receiving 482 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Kiran Virik Canada 13 264 154 112 63 60 25 493
Marianne Davies United States 14 482 1.8× 110 0.7× 138 1.2× 75 1.2× 77 1.3× 38 795
Scott R. Berry Canada 13 281 1.1× 72 0.5× 92 0.8× 65 1.0× 32 0.5× 30 497
Yueh‐Hsin Wang Taiwan 13 260 1.0× 60 0.4× 122 1.1× 92 1.5× 22 0.4× 24 540
HH Hansen Denmark 6 247 0.9× 59 0.4× 146 1.3× 97 1.5× 27 0.5× 10 514
Shani Alston United States 8 233 0.9× 59 0.4× 145 1.3× 64 1.0× 35 0.6× 13 661
Gábor Liposits Denmark 12 373 1.4× 51 0.3× 162 1.4× 49 0.8× 19 0.3× 48 586
Anke Rentsch Germany 10 288 1.1× 74 0.5× 89 0.8× 90 1.4× 19 0.3× 22 470
F. Cavalli Switzerland 11 119 0.5× 203 1.3× 62 0.6× 43 0.7× 103 1.7× 28 418
Nehal Masood Pakistan 14 341 1.3× 39 0.3× 201 1.8× 82 1.3× 71 1.2× 35 617

Countries citing papers authored by Kiran Virik

Since Specialization
Citations

This map shows the geographic impact of Kiran Virik's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Kiran Virik with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Kiran Virik more than expected).

Fields of papers citing papers by Kiran Virik

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Kiran Virik. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Kiran Virik. The network helps show where Kiran Virik may publish in the future.

Co-authorship network of co-authors of Kiran Virik

This figure shows the co-authorship network connecting the top 25 collaborators of Kiran Virik. A scholar is included among the top collaborators of Kiran Virik based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Kiran Virik. Kiran Virik is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
2.
3.
Sarfaty, Michal, Peter Hall, Kelvin Chan, et al.. (2018). Cost-effectiveness of Pembrolizumab in Second-line Advanced Bladder Cancer. European Urology. 74(1). 57–62. 49 indexed citations
4.
Virik, Kiran, et al.. (2018). P3.01-04 Immune Checkpoint Inhibitors (ICIs) in NSCLC: Immune Related Adverse Events (irAEs) and Outcomes. A Canadian Single Institution Experience. Journal of Thoracic Oncology. 13(10). S868–S868. 1 indexed citations
5.
Goldstein, Daniel A., Qiushi Chen, Turgay Ayer, et al.. (2017). Bevacizumab for Metastatic Colorectal Cancer: A Global Cost-Effectiveness Analysis. The Oncologist. 22(6). 694–699. 27 indexed citations
6.
Virik, Kiran & Robert B. Wilson. (2016). Bone loss and vitamin D deficiency post gastrectomy for gastro-esophageal malignancy.. Journal of Clinical Oncology. 34(4_suppl). 165–165. 1 indexed citations
7.
Tang, Patricia A., Steven J. Cohen, Christian Kollmannsberger, et al.. (2012). Phase II Clinical and Pharmacokinetic Study of Aflibercept in Patients with Previously Treated Metastatic Colorectal Cancer. Clinical Cancer Research. 18(21). 6023–6031. 67 indexed citations
8.
Saint‐Jacques, Nathalie, et al.. (2008). Waiting Times in Early-Stage Non-small Cell Lung Cancer (NSCLC). Journal of Thoracic Oncology. 3(8). 865–870. 32 indexed citations
9.
Tang, Patricia A., Steven J. Cohen, Georg A. Bjarnason, et al.. (2008). Phase II trial of aflibercept (VEGF Trap) in previously treated patients with metastatic colorectal cancer (MCRC): A PMH phase II consortium trial. Journal of Clinical Oncology. 26(15_suppl). 4027–4027. 35 indexed citations
10.
Younis, Tallal, et al.. (2008). Adjuvant Chemotherapy Uptake in Non-small Cell Lung Cancer. Journal of Thoracic Oncology. 3(11). 1272–1278. 33 indexed citations
11.
Skedgel, Chris, et al.. (2008). The Cost Burden of Trastuzumab and Bevacizumab Therapy for Solid Tumours in Canada. Current Oncology. 15(3). 136–142. 35 indexed citations
12.
Virik, Kiran, Chris Skedgel, & T. Younis. (2006). Economic evaluation of adjuvant chemotherapy in Stage III (SIII) colon cancer: Capecitabine versus 5FU/LV. Journal of Clinical Oncology. 24(18_suppl). 6046–6046. 3 indexed citations
13.
Virik, Kiran & Paul Glare. (2002). Profile and Evaluation of a Palliative Medicine Consultation Service Within a Tertiary Teaching Hospital in Sydney, Australia. Journal of Pain and Symptom Management. 23(1). 17–25. 32 indexed citations
14.
Virik, Kiran & Paul Glare. (2002). Requests for euthanasia made to a tertiary referral teaching hospital in Sydney, Australia in the year 2000. Supportive Care in Cancer. 10(4). 309–313. 16 indexed citations
15.
Harper, Peter, Christos S. Karapetis, Desmond Yip, et al.. (2001). Epirubicin, Cisplatin, and Prolonged or Brief Infusional 5-Fluorouracil in the Treatment of Carcinoma of Unknown Primary Site. Medical Oncology. 18(1). 23–32. 2 indexed citations
16.
Glare, Paul & Kiran Virik. (2001). Can we do better in end‐of‐life care? The mixed management model and palliative care. The Medical Journal of Australia. 175(10). 530–533. 15 indexed citations
17.
Virik, Kiran, Christos S. Karapetis, Stavroula Droufakou, & Peter Harper. (2001). AVASCULAR NECROSIS OF BONE: THE HIDDEN RISK OF GLUCOCORTICOIDS USED AS ANTIEMETICS IN CANCER CHEMOTHERAPY. International Journal of Clinical Practice. 55(5). 344–345. 8 indexed citations
18.
Glare, Paul & Kiran Virik. (2001). Independent Prospective Validation of the PaP Score in Terminally Ill Patients Referred to a Hospital-Based Palliative Medicine Consultation Service. Journal of Pain and Symptom Management. 22(5). 891–898. 95 indexed citations
19.
Virik, Kiran & Paul Glare. (2000). Pain management in palliative care. Reviewing the issues.. PubMed. 29(11). 1027–33. 4 indexed citations
20.
Virik, Kiran, Jennifer Turner, Raymond Garrick, & John P. Sheehy. (1999). Malignant transformation of craniopharyngioma. Journal of Clinical Neuroscience. 6(6). 527–530. 15 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Marianne Davies Breakdown of academic impact, for papers by Scott R. Berry Breakdown of academic impact, for papers by Yueh‐Hsin Wang Breakdown of academic impact, for papers by HH Hansen Breakdown of academic impact, for papers by Shani Alston Breakdown of academic impact, for papers by Gábor Liposits Breakdown of academic impact, for papers by Anke Rentsch Breakdown of academic impact, for papers by F. Cavalli Breakdown of academic impact, for papers by Nehal Masood
Rankless by CCL
2026